Gus Attridge

Who Gus Attridge is

Gus Attridge co-founded Aspen Pharmacare in 1997 and has been its deputy chief executive ever since. He is the second name on a company that has only ever had two — and he is the entry on this index that best illustrates what the finance half of an acquisitive business is actually worth.

Aspen is the largest pharmaceutical company in Africa. In the 2023 financial year it reported revenue of R40.7 billion; it employs around 9,100 people and, as at October 2021, operated 23 manufacturing facilities across 15 sites. It trades on the JSE as APN.

The other founder

The originating Aspen business was founded in 1997 by a small group including Attridge and Stephen Saad, alongside Steve Sturlese and a fourth shareholder. It listed on the JSE in 1998.

Attridge, a chartered accountant, took the finance side. Saad took the chief executive role and the public profile. Nearly three decades later both are still in post, which is the unusual part — and the reason both appear separately on this index.

Founding partnerships that survive this long are rare enough to be worth a moment. Most either break up over control or are diluted out by the capital needed to grow. Aspen did neither, through a hostile takeover, three cross-border acquisitions and a pandemic manufacturing contract.

Why the finance seat mattered at this particular company

Aspen did not grow by inventing medicines. It grew by buying them, and that makes the finance function the engine rather than the scorekeeper.

Look at the sequence. In 1999, two years old and one year listed, Aspen took over South African Druggists in a hostile bid worth R2.4 billion. In 2009 it acquired pharmaceutical assets from GlaxoSmithKline, paying £268 million in shares together with a manufacturing site at Bad Oldesloe in Germany. In 2010 it bought Australia’s Sigma Pharma for US$1.24 billion. By 2014 it was in 21 countries.

Every one of those is a financing problem before it is a commercial one. A two-year-old company does not mount a R2.4 billion hostile bid on cash flow; it does so on borrowed money and on a credible plan for servicing the debt afterwards. The GSK deal was paid in shares rather than cash — a structure that conserves money but hands a multinational a stake in your business, which is a negotiation about control as much as about price. And a company acquiring across four continents carries currency exposure on its revenues, its costs and its debts simultaneously.

Someone has to hold that together for twenty-five years. On this index the chief executives get the profiles and the finance directors generally do not; Aspen is a useful correction to that habit.

The generics model, and the vaccine

Aspen’s core business is generics: making medicines whose patents have expired, at a fraction of the originator’s price. There is no research gamble and no blockbuster upside — you win on manufacturing scale, regulatory competence, and the ability to register the same product in many countries at once, frequently selling to governments.

That mattered enormously in the country where Aspen was founded. Originator pricing assumes health budgets that South Africa did not have as it faced the largest HIV epidemic in the world. Generic manufacture changes the arithmetic rather than the science, and a domestic manufacturer changes it further, because the medicine is bought in rand from a plant inside the country.

From March 2021 Aspen took on the “fill and finish” of the Janssen COVID-19 vaccine — the final sterile stage of putting bulk substance into vials — and later that year announced a contract to produce 700 million doses by January 2023. It was the first serious demonstration that vaccine manufacturing capacity at that scale could sit in Africa.

Where the model is exposed

The structure that built Aspen also carries the risks, and they explain the share price’s volatility better than any single news story.

Generic manufacture is price-taking. There is no pricing power in making a product several other companies can also make, so margins depend on being the lowest-cost producer — a position that can be lost to a competitor in another country with cheaper inputs. Much of the revenue comes from governments and state tender processes, where one procurement decision can move a year’s earnings and payment terms are outside the seller’s control. Manufacturing at this scale is capital-hungry, and a plant that regulators suspend earns nothing while it is idle.

Then there is the balance sheet itself, which is the founder-financier’s particular problem. An acquisitive company carries debt, and debt carries covenants — contractual limits on the ratio of borrowings to earnings. A business whose earnings fall for reasons outside its control can breach a covenant without ever missing a payment, and a breach hands lenders the whip hand at the worst possible moment. Currency compounds it: a weaker rand flatters reported revenue from abroad while inflating both the cost of imported active ingredients and the rand value of foreign-denominated debt.

Managing that combination across twenty-odd countries for twenty-five years is the job. It is invisible when done well, which is the whole difficulty of writing about a finance director.

How Rateweb values him

Attridge is an executive director of a JSE-listed company, so his beneficial interest is disclosed in Aspen’s annual report under the JSE’s listing requirements. In principle this is among the better-evidenced entries here.

In practice it is not yet, for the same reason as Saad’s. Aspen is not among the twelve companies for which this index holds a market capitalisation, so his stake cannot be revalued from a live price — it sits as a fixed estimate, and the index marks it as such rather than letting it pass for a live figure. Our number is a provisional constant from the first build rather than a computed valuation.

Fixing it is a bounded task and it fixes two entries at once: Aspen’s market capitalisation, plus the disclosed directors’ interests for both founders, converts two fixed estimates into computed ones. See the methodology for why that distinction is the one this index cares most about.

One structural caveat applies here as it does to Adrian Gore: a long-serving executive’s holding is often not all freely held. Portions may be unvested, subject to lock-ins, or represented by options not yet exercised. A headline stake and a disposable stake are different quantities, and where the disclosure does not separate them, neither do we.

The quiet half of a partnership

Attridge gives few interviews and has none of the public profile his co-founder has. That is normal for the role and it has a consequence for this index worth stating.

Visibility and valuation accuracy are related, as Natie Kirsh’s entry showed at length. But the relationship runs through disclosure, not fame. Attridge is not a public figure and his shareholding is nonetheless a matter of public record, because he sits on a listed board. Kirsh was equally private and his was not, because his company was not listed.

Being unknown is not what makes a fortune hard to measure. Being unlisted is.

The exchange is a bargain, and it is worth spelling out because it underlies most of this index. A company that wants access to public money accepts public scrutiny in return: audited accounts, announcements of anything price-sensitive, and a register naming whoever holds a significant stake, directors included. That obligation is owed to shareholders, not to journalists — but it is a matter of public record, which is why an index like this one can be built at all.

Every entry here rests on which side of that bargain the person’s money sits. Two founders of the same company, equally private by temperament, are equally visible to us because they chose to list. Two others of comparable wealth may be invisible because they never needed to.

What we do not know

The current size of his shareholding, which needs reading out of the latest annual report. How much is vested and disposable rather than merely held. What he owns outside Aspen — private investments and property are not disclosed in any form we can value. And how any of it is structured between him, family members and trusts.

We also make no attempt to model tax. A founder’s stake carries an embedded capital gains liability that would only crystallise on sale, so a headline net worth is a gross figure rather than what anyone would actually receive for it. That is true of every entry on this index and is worth stating rather than leaving implied.

If you can improve this with a public disclosure, tell us.